Healthcare
Sarepta Therapeutics, Inc.(SRPT)
Live Price
Offline$15.31
+2.07% today
1Y Change
-24.75%
Window
Jun 20, 2025 โ Jun 10, 2026
- Market Cap
- $2.26B
- Revenue Growth
- +15.6%
- EPS Growth
- -388.7%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 20, 2025 โ Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sarepta Therapeutics, Inc. (SRPT) is a Healthcare stock with a market cap of $2.26B and listed on NASDAQ. The stock last traded around $15.31 and down 24.8% across the available one-year price window (Jun 20, 2025 โ Jun 10, 2026). Baseline metrics include revenue growth of +15.6%, EPS growth of -388.7%, a dividend yield of 0.0%. What stands out right now is revenue +15.6%, EPS -388.7%, free cash flow +12.8% with operating margin -31.8% and ROIC -30.9%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SRPT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+15.6% vs +7.6% peer median
Operating Margin
Below sector median
-31.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +15.6% and EPS is at -388.7%, with operating margin around -31.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -18.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +5.7% | -12.2% | -25.5% |
2026 Feb 25, 2026 | -247.6% | -8.0% | -15.2% | +25.3% |
2025 Nov 3, 2025 | -1400.0% | -33.7% | -29.4% | -16.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SRPT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SRPT Max Drawdown
-45.70%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SRPT and SPY.
Company Overview
Sarepta Therapeutics, Inc.
NASDAQ Global Select
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
- Leadership
- Douglas S. Ingram
- IPO Date
- Jun 4, 1997
- Employees
- 1.4k
- Street Address
- 215 First Street
- Mailing
- Cambridge, MA, 02142
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 274 4000
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.0
- Price/Book
- 2.0
Growth
- Revenue
- +15.6%
- EPS
- -388.7%
- Free Cash Flow
- +12.8%
Profitability
- Gross Margin
- 61.8%
- Operating Margin
- -31.8%
- Net Margin
- -32.5%
- ROE
- -57.5%
- ROIC
- -30.9%
Balance Sheet
- Debt/Equity
- 0.91
- Current Ratio
- 2.32
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.